Group 1 - Green Micro-Nano Technology Co., Ltd. has completed a Pre-A round financing of several tens of millions, led by Jinqiao Fund, to expand production lines and promote market presence [2] - The company was established in October 2022 and its core technology is incubated from the research team of Academician Zhang Jun at the Chinese Academy of Sciences [2][3] - The core team has comprehensive capabilities from R&D to commercialization, with expertise in the preparation of micro-nano cellulose functional materials using a novel ionic liquid green processing technology [3] Group 2 - Green Micro-Nano focuses on four major business areas: paper products, daily chemical personal care, industrial additives, and life sciences, leveraging unique forms and properties of its core materials [3] - The company has established collaborations with several consumer electronics supply chain companies and international skincare brand manufacturers, achieving head customer validation and product testing [5] - In the paper products sector, the company has shifted from hundred-kilogram orders to ton-level orders, particularly in luxury packaging and consumer electronics packaging [5] Group 3 - The 11th Bio-based Industry Conference and Exhibition will be held in May 2026 in Shanghai, focusing on the innovation and development of the bio-based industry [6] - The event will feature 11 thematic forums covering the entire industry chain from technology to application, including key chemicals and materials, international cooperation, and biodegradable materials [6][9] - There will be 7 concurrent activities, including a bio-based industry exhibition showcasing over 1000 new products and a high-level strategic seminar [6][9]

当新质 生产力成为高质量发展的关键引擎，当青年科技人才在创新发展中的生力军作用愈发凸显， 如何发现青年之智？如何点燃创新之力？ DT新材料旗下生物基和生物制造产业科技服务平台， 是行业最重要 的资源和信息枢纽之一 。至今 为止，我们在生物基大会、非粮生物质论坛、合成生物学与绿色生物制造论坛、材视等多场主创活动 上举办多届青年主题论坛，已有 500+位 创新青年科学家线上线下分享前沿科技与进展，并促进产 业、投资和科研等多方交流、关注与对接。 关键词 | 生物基大会 |青年科学家论坛 2026年5月2 0-22 日 ， 2026（ 第11届）生物基大会暨展览 （简称：Bio-based 2026）将于 上海举办，同期将举办 " 第5届生 物基前沿科技 青年科学家论坛 （ Bio-based Youngs 2026 ） "。 这个论坛的使命非常简单： 让生物基青年科学家被看见 。 你可能刚拿到博士学位不久，手里有几篇不错的SCI论文，也申请了几个专利，但总感觉这些成果只 是躺在数据库里。 或者你已经是副教授，正在为下一个国自然项目发愁，想知道除了论文之外还有什么路径能证明自己 的价值。 你可能会有两个问题： 第一 ...

Core Viewpoint - The article emphasizes the importance of the Bio-based Young Scientists Forum as a platform for young researchers in the bio-based materials industry to showcase their innovations and connect with industry stakeholders, thereby enhancing their visibility and opportunities for collaboration [4][35]. Group 1: Importance of the Forum - The bio-based industry is experiencing explosive growth, with a reported increase of 29.8% in the first three quarters of 2025 and a monthly growth of 25.4% in November [9][10]. - Young researchers face a dilemma with a low funding success rate of 14-16% for national science projects, making it crucial to establish visibility in the industry [11][12]. - There is a significant gap in the commercialization of academic patents, with only 3.9% of university patents being industrialized compared to nearly 50% for enterprises, highlighting the need for better connections between academia and industry [14]. Group 2: Benefits of Participation - Participants will have a 10-minute platform to present their cutting-edge technologies, allowing for concise communication of their core innovations [15][16]. - The forum provides expert reviews and feedback from authoritative figures in the field, with awards for outstanding presentations, including a first prize of 2000 yuan [18][19]. - There will be real opportunities for industry connections, with over 1000 successful matches in the bio-based sector previously facilitated by the organizing company [20]. - Participants will receive dedicated promotional support, including custom posters and social media exposure, reaching over 200,000 individuals across various sectors [21][23]. Group 3: Target Audience - The forum is aimed at young scholars with research achievements in bio-based chemicals, materials, and additives, as their work may align with the needs of chemical companies undergoing transformation [26][28]. Group 4: Participation Details - The forum will take place on May 20, 2026, in Shanghai, as part of the 11th Bio-based Conference and Exhibition [30]. - Registration is straightforward, requiring participants to select the "Young Scientists Forum" option when signing up [31].

Core Viewpoint - The article discusses the recent B-round financing of Zhuhai Maidefa Biotechnology Co., Ltd. (referred to as "Maidefa"), highlighting its unique positioning in the pharmaceutical and PHA (polyhydroxyalkanoates) materials market, and the strategic partnerships that support its growth [4][7][8]. Financing and Growth - Maidefa successfully completed its B-round financing, with investments from China Taiping Innovation and Guangzhou Pharmaceutical Capital, although the specific amount remains undisclosed [4][7]. - The company has a history of financing rounds, including an angel round in March 2021, a series A round in May 2022, and an A+ round in December 2023, indicating a steady growth trajectory [5][6]. Product Lines and Market Position - Maidefa operates three main product lines: industrial-grade PHA, medical-grade PHA, and beta-hydroxybutyrate (β-HB), which together form a complete PHA value chain [14]. - The industrial-grade PHA is used in biodegradable packaging and has gained recognition from major companies like Walmart and Costco [16]. - The medical-grade PHA is a core differentiator for Maidefa, making it the world's first supplier of medical-grade PHA materials, with necessary regulatory approvals from both China and the USA [18]. - The beta-hydroxybutyrate product, branded as "Sainao Si," targets brain health and has been launched in markets including Macau and the USA [19]. Strategic Partnerships - Maidefa's third-largest shareholder is Lijun Pharmaceutical Group, which has been involved since the company's inception, indicating a deep-rooted strategic alignment in the pharmaceutical sector [10][12]. - Guangzhou Pharmaceutical Capital's investment is expected to provide not only financial support but also additional resources in the pharmaceutical domain, enhancing Maidefa's market capabilities [13]. Milestones and Future Plans - The company has achieved significant milestones, including the establishment of a cleanroom for medical-grade PHA production and the expansion of its production capacity for industrial-grade PHA [23][25]. - The successful completion of the B-round financing is seen as a new impetus for Maidefa's industrialization in the PHA sector, reinforcing its dual strategy of "pharmaceutical + PHA" [27].

Core Viewpoint - Zhuhai MedPHA Biotechnology Co., Ltd. has successfully completed a Series B financing round, which is seen as a recognition of its technological strength and market prospects, as well as a significant step in accelerating its industrialization process [5][28]. Group 1: Financing History - MedPHA completed its angel round financing in March 2021 [3]. - In May 2022, the company raised tens of millions of RMB in Series A financing [3]. - In December 2023, MedPHA completed a Series A+ financing round, raising several tens of millions of RMB, led by Huafa Group's investment platform [3]. Group 2: Company Positioning - The name "MedPHA" combines "Medicine" and "PHA," indicating the company's unique positioning as an innovative enterprise in both pharmaceuticals and PHA materials [6]. - The third-largest shareholder, Lijun Pharmaceutical Group, has been involved since the company's inception, influencing its strategic direction from a genetic level [8]. Group 3: Shareholder Structure - The largest shareholder, Zhuhai Hengqin Baomei Enterprise Management, holds 50.63% of the shares [9]. - Lijun Pharmaceutical Group holds 5.63% of the shares, indicating a long-term strategic partnership [9][10]. - Other notable shareholders include Zhuhai Hengqin Baoli Enterprise Management and Zhuhai Huajin Lingjian Equity Investment [9]. Group 4: Product Lines - MedPHA has three main product lines: industrial-grade PHA, medical-grade PHA, and beta-hydroxybutyrate health-active small molecules [11]. - Industrial-grade PHA is used in biodegradable packaging and has gained recognition from major companies like Walmart and Costco [13]. - Medical-grade PHA is a core differentiated product, with MedPHA being the first global supplier to receive regulatory approvals from the National Medical Products Administration and the FDA [16]. - The beta-hydroxybutyrate product, branded as "Sainao Si," targets brain health and has been launched in Macau and the United States [18]. Group 5: Milestones Achieved - MedPHA has achieved significant milestones in 2025, including medical certification, capacity expansion, and the completion of Series B financing [21][25][28]. - The company successfully passed ISO 13485:2016 certification for its medical device quality management system, a key qualification for entering the medical device industry [21]. - The industrial-grade PHA production capacity has been expanded to over 2,000 tons, and a cleanroom for medical-grade PHA has been established [25].

Core Viewpoint - Ningbo Changya New Materials Technology Co., Ltd. (Changya Co., Ltd.) has submitted an application for the first public offering of stocks and listing guidance, which was accepted by the Ningbo Securities Regulatory Bureau on December 29, 2025 [1]. Company Basic Information - Changya Co., Ltd. was established on January 14, 2013, with a registered capital of 111.34 million yuan. The legal representative is Xu Jianhai, and the company is located at 766 Dongsheng Road, Jiao Chuan Street, Zhenhai District, Ningbo, Zhejiang Province [2]. - The controlling shareholder is Ningbo Changya Asset Holding Co., Ltd., which directly holds 49.54% of the shares [2]. - The company specializes in the research, production, and sales of plastic dining utensils, biodegradable dining utensils, and paper dining utensils, primarily producing paper and PLA disposable tableware [4]. IPO Application Progress - Changya Co., Ltd. previously submitted an IPO application to the Shenzhen Stock Exchange in June 2023. However, in May 2024, the company decided to withdraw the application due to changes in the capital market environment and its operational situation, leading to the termination of the project in June 2024 [3][4]. Financial Performance - The company's revenue for the years 2020, 2021, 2022, and the first nine months of 2023 were 512.15 million yuan, 623.03 million yuan, 918.64 million yuan, and 536.39 million yuan, respectively. The net profit attributable to the parent company for the same periods was 73.04 million yuan, 53.49 million yuan, 124.67 million yuan, and 72.07 million yuan [6]. - The total assets as of September 30, 2023, were 1,013.60 million yuan, with equity attributable to the parent company at 607.29 million yuan. The asset-liability ratio was 42.50% [7]. Client Base - The main customer groups include chain supermarkets, disposable material suppliers, and distributors of food packaging products. Notable clients include Dollar General, KFC, Burger King, Panda Express, and others [8][10]. - The company's products are primarily exported, with overseas sales accounting for 95.80%, 95.96%, 98.25%, and 96.95% of the main business revenue in the respective years [11].

Core Viewpoint - UPM has launched a commercial production facility for wood-based chemicals in Germany, marking a significant investment in the bio-based industry, particularly focusing on high-value products derived from lignin and sugars [2][10]. Group 1: Investment and Production - UPM's bio-refinery in Leuna represents an investment of €1.3 billion (approximately 10.7 billion RMB) with an annual capacity of 220,000 tons, making it the largest bio-chemical industrial investment project in Europe [2]. - The facility aims to produce four main products: bio-based ethylene glycol, bio-based propylene glycol, lignin-based functional fillers, and industrial sugars [2]. Group 2: Market Potential - The global lignin market is projected to grow from $1.13 billion in 2024 to $1.62 billion by 2032, with a compound annual growth rate (CAGR) of 4.1% [3]. - Bio-based ethylene glycol is expected to see significant growth, with its market size forecasted to increase from $3.1 billion in 2024 to $9.2 billion by 2033, reflecting a CAGR of 14.2% [3]. Group 3: Resource Utilization Challenges - The traditional paper industry faces challenges in resource utilization, as only 70% of a tree is used for pulp, while the remaining 30% is often burned for energy [5]. - Lignin, a byproduct of the pulping process, is typically discarded or burned, leading to significant waste in the industry [6]. Group 4: Technological and Market Challenges - High-value utilization of lignin faces technical and cost barriers, as traditional methods damage its structure, making it difficult to convert into valuable chemicals [8]. - Historical attempts by major chemical companies to develop cellulose-based ethanol have largely failed, highlighting the need for accurate market assessments and customer willingness to pay for green products [9]. Group 5: UPM's Strategic Focus - UPM's strategy focuses on producing high-value chemicals rather than fuel ethanol, targeting the growing market for bio-based ethylene glycol and propylene glycol [10][15]. - The bio-refinery employs advanced techniques to extract sugars and separate lignin, converting them into renewable chemicals that can replace fossil-based products [12]. Group 6: Product Advantages - UPM's bio-based ethylene glycol has a negative carbon footprint of -0.3 kg CO2e/kg, significantly lower than fossil-based alternatives, which emit 3.0-3.7 kg CO2e/kg [17]. - The renewable functional filler derived from lignin can replace carbon black and silica in rubber and plastics, offering a carbon footprint reduction of 48-58% [21]. Group 7: Future Outlook - UPM plans to launch more commercial products from the Leuna facility in the first half of 2026, with full operational capacity expected to reach 220,000 tons of advanced bio-chemicals annually [23]. - The Chinese market, with its vast lignin resources, is also exploring similar transformations from waste to valuable chemicals, potentially leading to competitive advancements in the bio-based sector [25].

Core Viewpoint - UPM's investment in a biorefinery in Germany represents a strategic shift towards high-value biochemicals, particularly lignin and bio-based glycols, amidst a declining traditional paper industry [4][11]. Group 1: Investment and Market Potential - UPM's biorefinery in Leuna, Germany, has an investment of €1.3 billion (approximately 10.7 billion RMB) and an annual capacity of 220,000 tons, making it the largest biochemicals industrial investment project in Europe [4]. - The global lignin market is projected to grow from $1.13 billion in 2024 to $1.62 billion by 2032, with a compound annual growth rate (CAGR) of 4.1% [4]. - The bio-based ethylene glycol market is expected to expand from $3 billion in 2024 to $9.2 billion by 2033, with a CAGR of 14.2% [5]. Group 2: Resource Utilization Challenges - The traditional paper industry faces a resource utilization dilemma, where only 70% of a tree is used for pulp, leaving 30% (branches) underutilized, primarily burned for energy [7]. - During the pulping process, lignin is removed, leading to significant waste, as it is typically incinerated for heat recovery [8][9]. Group 3: High-Value Utilization Challenges - The high-value utilization of lignin faces three main challenges: technical and cost barriers, market feasibility, and the need for precise market assessments [10]. - UPM's strategy focuses on converting lignin and sugars into high-value chemicals rather than biofuels, targeting the chemical market instead [11]. Group 4: Product Development and Market Strategy - UPM's biorefinery will produce bio-based ethylene glycol and functional fillers, with a focus on market growth and sustainability [14]. - Bio-based ethylene glycol has a negative carbon footprint of -0.3 kg CO2e/kg, significantly lower than fossil-based alternatives [18]. - The renewable functional filler can replace carbon black and silica in rubber and plastics, offering a carbon footprint reduction of 48-58% [23]. Group 5: Commercialization and Future Outlook - The Leuna biorefinery is set to start commercial production in December 2025, with plans for additional products to be launched in the first half of 2026 [26]. - Chinese companies are encouraged to follow UPM's model to transform lignin from waste to valuable chemicals, leveraging the country's vast agricultural waste resources [28].

Core Viewpoint - The bio-based 1,3-propanediol (PDO) industry in China is transitioning from "technology validation" to "scale production" by 2025, driven by the demand for green transformation in downstream markets such as textiles and cosmetics [2]. Group 1: PDO Production Capacity and Technological Advances - By 2025, multiple companies are accelerating the construction of large-scale production bases for bio-based PDO, with significant investments and technological breakthroughs [4][5]. - Companies like Qingda Zhixing and Heng Carbon Technology have successfully developed fermentation methods for PDO production, breaking the technological monopoly of foreign firms [5][6]. - Heng Carbon Technology has established a unique production base with an annual capacity of 15,000 tons, utilizing a revolutionary "three non-four no" technology that is highly environmentally friendly [6][7]. Group 2: Market Expansion and Applications - PDO is widely applicable in various industries, including polyester, cosmetics, polyurethane, pharmaceuticals, and coatings [10]. - The global bio-based PTT market, which utilizes PDO as a core monomer, is projected to grow from approximately 3.4 billion yuan in 2023 to 8.3 billion yuan by 2030, with a compound annual growth rate of 13.1% [13]. - Companies are forming strategic partnerships to create integrated industrial bases that enhance competitiveness in the bio-based PTT market [13][14]. Group 3: Emerging Companies and Innovations - New companies are emerging with innovative production techniques, such as Shandong Xiangchi Jianyuan Biotechnology, which is implementing advanced fermentation methods to enhance production efficiency [9]. - Zhongke Baiyijin has successfully produced bio-based PDO with a purity of 99.9% using biomass as a raw material [9]. - The industry is witnessing a structural expansion in downstream markets, particularly in textiles and cosmetics, benefiting from reduced raw material costs and increased production capacity [14].

Core Viewpoint - The article discusses the significant transition of China's bio-based 1,3-propanediol (PDO) industry from "technology validation" to "scale production" by 2025, highlighting the increasing demand for green transformation in downstream markets such as textiles and cosmetics [4][6]. Group 1: Industry Development - By 2025, multiple companies are advancing the construction of large-scale production bases for bio-based PDO, with the recent environmental assessment announcement for Yifeng Jiatai's 30,000 tons/year PDO project marking the fourth such project in China [4][6]. - Domestic companies like Dongfang Shenghong, Qingda Zhixing, and Juhua Co. have increased R&D investments to achieve bio-fermentation production of PDO, breaking the technological monopoly of foreign firms [7][8]. Group 2: Technological Innovations - Qingda Zhixing is noted for mastering both glycerol and sugar fermentation technologies for PDO production, with established production bases in Shandong and Shanxi [8]. - Hengcarbon Technology has developed a revolutionary third-generation PDO production technology with minimal environmental impact, achieving a production capacity of 15,000 tons/year [8]. - The next phase of bio-based PDO production will focus on "multi-raw material" technology to reduce cost risks [9]. Group 3: Market Expansion - PDO is widely applicable in various industries, including polyester, cosmetics, polyurethane, pharmaceuticals, and coatings [11]. - The global bio-based PTT market, which utilizes PDO as a core monomer, is projected to grow from approximately 3.4 billion yuan in 2023 to 8.3 billion yuan by 2030, with a compound annual growth rate of 13.1% [14]. - Companies like Qingda Zhixing and Dongfang Shenghong are forming strategic partnerships to create integrated industrial bases for bio-based materials, ensuring competitive advantages in the market [15][16].